Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global Device Approvals Snapshot: 14 May – 20 May 2019; FDA Approves Stryker’s Neuroform Atlas Stent

Executive Summary

A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. This week, the US FDA approved Stryker’s Neuroform Atlas stent system to be used with embolization coils to treat wide-necked intracranial aneurysms.

You may also be interested in...



FDA Urges Caution in Some Neurovascular Stent Use

US FDA has issued new guidelines to providers because some patients experienced strokes or died after being treated for unruptured brain aneurysms with some neurovascular stents.

Personal Care Next Target For UK Competition Authority ‘Greenwashing’ Audit

Manufacturers of UK personal care products watch out, the Competition and Markets Authority is on the look-out for false, exaggerated and/or vague sustainability claims, and may be targeting bigger players to make an example for the rest of the sector. And consumer health might be next. HBW Insight returns to advice from marketing expert Jo Stephenson on how to avoid greenwashing, based on the CMA's own extensive Green Claims Code.

UK MHRA’s New And Increased Medtech Fees In Force in April

One outcome of last year’s public consultation on UK MHRA fees is a hefty uplift in charges payable by medtech manufacturers for 2023, and index-linked increases thereafter.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125128

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel